<<6-(3,4,5-triphenyl-1H-pyrazol-1-yl)hexyl>sulfinyl>acetic acid | 134701-80-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: <<6-(3,4,5-triphenyl-1H-pyrazol-1-yl)hexyl>sulfinyl>acetic acid
• 英文别名: 2-[6-(3,4,5-Triphenylpyrazol-1-yl)hexylsulfinyl]acetic acid
• CAS: 134701-80-7
• 化学式: C₂₉H₃₀N₂O₃S
• 分子量: 486.635
• InChiKey: OBCBELVPKZPITC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  35
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  91.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  ethyl 3,4,5-triphenyl-1H-pyrazole-1-hexanoate 在 Oxone 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 溴 、 potassium carbonate 、 三苯基膦 、 potassium iodide 作用下， 以 甲醇 、 乙醚 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 20.25h， 生成 <<6-(3,4,5-triphenyl-1H-pyrazol-1-yl)hexyl>sulfinyl>acetic acid
  参考文献：
  名称：

  Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic

  摘要：

  A series of phenylated pyrazoloalkanoic acid derivatives were synthesized and evaluated as inhibitors of ADP-induced human platelet aggregation. 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (8d), with an 1C50 of 0.4-mu-M, was the most potent inhibitor identified in this study. Biochemical studies determined that 8d increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concentration-dependent fashion. Displacement of [H-3]iloprost by 8d from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biological action. Structure-activity studies demonstrated that the minimum structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an omega-alkanoic acid side chain eight or nine atoms long. Potency depended upon both side-chain length and its topological relationship with the two phenyl rings.

  DOI：

  10.1021/jm00080a028

文献信息

• Arylpyrazole derivatives as platelet aggregation inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：EP0417449B1

  公开（公告）日：1995-02-15
• US4994482A
  申请人：——

  公开号：US4994482A

  公开（公告）日：1991-02-19
• US5071866A
  申请人：——

  公开号：US5071866A

  公开（公告）日：1991-12-10
• Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic
  作者：Nicholas A. Meanwell、Michael J. Rosenfeld、J. J. Kim Wright、Catherine L. Brassard、John O. Buchanan、Marianne E. Federici、J. Stuart Fleming、Steven M. Seiler

  DOI：10.1021/jm00080a028

  日期：1992.1

  A series of phenylated pyrazoloalkanoic acid derivatives were synthesized and evaluated as inhibitors of ADP-induced human platelet aggregation. 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (8d), with an 1C50 of 0.4-mu-M, was the most potent inhibitor identified in this study. Biochemical studies determined that 8d increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concentration-dependent fashion. Displacement of [H-3]iloprost by 8d from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biological action. Structure-activity studies demonstrated that the minimum structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an omega-alkanoic acid side chain eight or nine atoms long. Potency depended upon both side-chain length and its topological relationship with the two phenyl rings.